Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling

Satoshi Takahashi, Rintaro Noro, Masahiro Seike, Chao Zeng, Masaru Matsumoto, Akiko Yoshikawa, Shinji Nakamichi, Teppei Sugano, Mariko Hirao, Kuniko Matsuda, Michiaki Hamada, Akihiko Gemma

Abstract

Introduction: Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is an intractable challenge for many clinical oncologists. The mechanisms of resistance to EGFR-TKIs are complex. Long non-coding RNAs (lncRNAs) may play an important role in cancer development and metastasis. However, the biological process between lncRNAs and drug resistance to EGFR-mutated lung cancer remains largely unknown.

Methods: Osimertinib- and afatinib-resistant EGFR-mutated lung cancer cells were established using a stepwise method. Microarray analysis of non-coding and coding RNAs was performed using parental and resistant EGFR-mutant non-small cell lung cancer (NSCLC) cells and evaluated by bioinformatics analysis through medical-industrial collaboration.

Results: Colorectal neoplasia differentially expressed (CRNDE) and DiGeorge syndrome critical region gene 5 (DGCR5) lncRNAs were highly expressed in EGFR-TKI-resistant cells by microarray analysis. RNA-protein binding analysis by medical-industrial collaboration revealed eukaryotic translation initiation factor 4A3 (eIF4A3) bound overlappingly to CRNDE and DGCR5. The CRNDE downregulates the expression of eIF4A3, mucin 1 (MUC1), and phospho-EGFR. Inhibition of CRNDE activated the eIF4A3/MUC1/EGFR signaling pathway and apoptotic activity, and restored sensitivity to EGFR-TKIs.

Conclusions: The results showed that lncRNA CRNDE is associated with the development of resistance to EGFR-TKIs in EGFR-mutant NSCLC cells. CRNDE may be a novel therapeutic target to conquer EGFR-mutant NSCLC.

Introduction

For patients with lung cancer harboring EGFR mutations, Tyrosine Kinase Inhibitors (TKIs) like afatinib and osimertinib are standard-of-care treatments that initially show great efficacy. However, the "intractable challenge" is acquired resistance: the cancer eventually finds a way to bypass the drug. While some resistance mechanisms, such as secondary mutations, are well-documented, many cases remain unexplained. This study explores the "dark matter" of the genome—long non-coding RNAs (lncRNAs). These transcripts do not code for proteins but act as powerful regulatory switches. The authors sought to identify specific lncRNAs that orchestrate the bypass signaling pathways allowing cancer cells to survive TKI treatment.

Methods and Materials

The study employed a multi-disciplinary approach combining bench-top biology with bioinformatics. The team established afatinib-resistant (AR) and osimertinib-resistant (OR) lung cancer cell lines (PC-9 and HCC827) using a stepwise method, increasing drug concentrations over six months until the cells were significantly more resistant than their parental counterparts.

Table 1: IC50 values and mutation status of parental and resistant NSCLC cell lines.

Microarray analysis was performed to screen over 27,000 mRNAs and 25,000 lncRNAs to identify expression differences between sensitive and resistant cells. The researchers utilized several public and custom-built genomic resources, including LNCipedia, Gencode, and StarBase v2.0. The study's microarray data has been deposited in the NCBI Gene Expression Omnibus (GEO) under accession number GSE163913.

Key Insights: The CRNDE-eIF4A3 Axis

The most striking finding was that the lncRNA CRNDE binds directly to eIF4A3 (eukaryotic translation initiation factor 4A3). While eIF4A3 is typically known for its role in mRNA splicing and decay, here it acts as a bridge in the resistance pathway. Through medical-industrial collaboration, bioinformatics tools predicted and analyzed RNA-protein binding interactions, identifying proteins that interact with top lncRNA candidates.

Table 2: Proteins predicted to bind with lncRNAs CRNDE and DGCR5, showing overlapping binding partners like eIF4A3.

Usually, resistance involves activating growth pathways. However, the authors found that in resistant cells, CRNDE actually downregulates the eIF4A3/MUC1/EGFR signaling axis. Although another lncRNA (DGCR5) was also elevated in resistant cells, silencing it did not restore drug sensitivity, highlighting CRNDE as the primary functional driver in this specific resistance context.

Key Results and Functional Validation

  • Expression Levels: CRNDE was significantly overexpressed in both acquired resistant lines and "intrinsically" resistant cells.
  • Effective Knockdown: Using siRNA to silence CRNDE reduced its expression by 90% in resistant HCC827 cells.
  • Restoring Sensitivity: Inhibiting CRNDE significantly lowered the IC50 for both afatinib and osimertinib. This inhibition reactivated the eIF4A3/MUC1/EGFR pathway, which paradoxically triggered apoptosis (programmed cell death).
  • Apoptosis Induction: Silencing CRNDE led to a measurable increase in markers of cell death, such as cleaved PARP and cleaved caspase 3, especially when combined with osimertinib treatment.

Discussion and Future Directions

While the results are compelling, the authors acknowledge that the study was conducted entirely in vitro. The next critical step is to confirm whether CRNDE is similarly overexpressed in clinical samples from patients who have failed TKI therapy. Future studies using animal models (mouse xenografts) are needed to see if CRNDE inhibition can shrink resistant tumors in a living system. Additionally, the exact molecular mechanism by which eIF4A3 regulates MUC1 expression in this context remains a subject for deeper investigation.

In summary, this research provides a new piece of the puzzle in lung cancer resistance, suggesting that targeting the non-coding portion of the genome might be the key to extending the effectiveness of current targeted therapies.

Summary updated

Abstract

(1) Background: Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is an intractable problem for many clinical oncologists. The mechanisms of resistance to EGFR-TKIs are complex. Long non-coding RNAs (lncRNAs) may play an important role in cancer development and metastasis. However, the biological process between lncRNAs and drug resistance to EGFR-mutated lung cancer remains largely unknown. (2) Methods: Osimertinib- and afatinib-resistant EGFR-mutated lung cancer cells were established using a stepwise method. A microarray analysis of non-coding and coding RNAs was performed using parental and resistant EGFR-mutant non-small cell lung cancer (NSCLC) cells and evaluated by bioinformatics analysis through medical-industrial collaboration. (3) Results: Colorectal neoplasia differentially expressed (CRNDE) and DiGeorge syndrome critical region gene 5 (DGCR5) lncRNAs were highly expressed in EGFR-TKI-resistant cells by microarray analysis. RNA-protein binding analysis revealed eukaryotic translation initiation factor 4A3 (eIF4A3) bound in an overlapping manner to CRNDE and DGCR5. The CRNDE downregulates the expression of eIF4A3, mucin 1 (MUC1), and phospho-EGFR. Inhibition of CRNDE activated the eIF4A3/MUC1/EGFR signaling pathway and apoptotic activity, and restored sensitivity to EGFR-TKIs. (4) Conclusions: The results showed that CRNDE is associated with the development of resistance to EGFR-TKIs. CRNDE may be a novel therapeutic target to conquer EGFR-mutant NSCLC.
BibTeX
@inproceedings{takahashi2021long,
  author = {Satoshi Takahashi and Rintaro Noro and Masahiro Seike and Chao Zeng and Masaru Matsumoto and Akiko Yoshikawa and Shinji Nakamichi and Teppei Sugano and Mariko Hirao and Kuniko Matsuda and Michiaki Hamada and Akihiko Gemma},
  title = {{Long Non-Coding RNA CRNDE Is Involved in Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant Lung Cancer via eIF4A3/MUC1/EGFR Signaling}},
  booktitle = {Research Square},
  year = {2021},
  doi = {10.21203/rs.3.rs-137571/v1},
}
Figure